Regenicin Inc (RGIN) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access RGIN Annual Balance Sheets →
Examining balance sheet movements between Regenicin Inc and Mar 31 2022 reveals how Mar 31 2023 adjusts its asset composition and liability profile.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2023)
(Dec 31 2022) (Sep 30 2022) (Jun 30 2022) (Mar 31 2022)
Assets
Cash & cash equivalent10.88
Cash & Short-term Investments10.00
Other Current Assets0.00
Total Current Assets10.88
Other Assets, Noncurrent0.98
Common Stock Receivable0.00
Total Assets11.86
Liabilities
Accounts Payable, Current AC0.00
Accrued Liabilities, Current4.89
Short-term Debt0.19
Other Liabilities, Current12.99
Total Current Liabilities18.07
Long-term debt0.12
Total Long-term Debt0.12
Deferred Income12.53
Total Liabilities18.19
Stockholders' Equity
Series A Preferred Stock Value0.00
Common Stock Value0.16
Treasury Stock Value0.00
Additional Paid In Capital Common Stock10.21
Retained Earnings / Accumulated Deficit-16.57
Other Equity0.00
Common Stockholder's Equity-6.21
Total Stockholder's Equity-6.21
Liabilities & Stockholder's Equity11.86
4 historic quarters locked

Sign in to unlock the full Regenicin Inc balance sheet history.

About Regenicin Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001662252-23-000017

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.